Researchers across campus are taking a One WVU approach to solving important problems and saving lives. At its core, an experimental therapeutics platform that integrates multiple disciplines from chemistry and biology to the health sciences and cancer institute.
Assistant Vice President of Experimental Therapeutics Dr. Paul Lockman explained the importance of the collaboration and its mission during his presentation, “Focus on Experimental Therapeutics.” The talk was part of the West Virginia University Office of Research and Graduate Educations’ speaker series, Evening of Science.
Lockman, who is also the senior associate dean of research in the WVU School of Pharmacy and associate director of the WVU Cancer Institute, will lead the efforts. The program’s overarching mission is to create a rich research environment for faculty and students to interact with regard to molecular science and drug development; create and discover new therapeutic drugs or develop those that already exist, support clinical trial activity and strengthen community partnerships.
Attendees toured the newly renovated therapeutics lab which currently houses four chemists and two scientists who design drugs with computers. Trainees in the space include all levels from post-doctoral fellows to undergraduate students. $1.25 million has been invested in the lab to date.
Now accepting abstracts for the poster session of the 54th Van Liere Research Conference, which will be held March 21 and 22 at the WVU Health Sciences Center. Deadline to submit is Feb.15.
Lori Hazlehurst, PhD, Professor (WVU School of Pharmacy - Pharmaceutical Sciences and Co-Leader of the WVU Cancer Institute Research Program the Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program) has been named as the Associate Director for Basic Research at the WVU Cancer Institute. In this role, Hazlehurst will work closely with Dr. Richard Goldberg, institute director, and the leadership team of the WVU Cancer Institute to implement strategic goals to increase the impact of basic and translational cancer research at WVU. The primary strategy is to increase the number of NIH funded investigators focused on cancer research at WVU.
The training will highlight the importance of compliance with U.S. export laws and regulations, HSC faculty and staff’s personal responsibilities, and the processes designed to assist them. In particular, the information will look at how export regulations intersect with research, travel abroad, and the ways the Export Control office works with the Office of Global Affairs in the visa process for J-1 scholars and H-1B employees working in each school at HSC.